Update on bladder cancer diagnosis and management
|
|
- Blake Ferguson
- 5 years ago
- Views:
Transcription
1 7 Update on bladder cancer diagnosis and management RICHARD T. BRYAN Although the basis of the diagnosis and management of urothelial bladder cancer has remained unchanged for two decades or more, there have been some subtle but important changes in several components of these pathways over the past five to ten years, as outlined in this review. In the western world, bladder cancer is the fourth most common cancer in men and ninth most common cancer in women, 1 with a rising global incidence. 2,3 In the UK, the disease accounts for approximately new cases and 5000 deaths per year (Cancer Research UK). The cardinal symptom of urothelial bladder cancer (UBC) is painless visible haematuria, occurring in more than 80 per cent of patients at presentation, 4,5 and requiring prompt investigation, most often in a haematuria clinic setting. 6 A small but significant proportion of patients present with irritative, urinary tract infection (UTI)- like symptoms in the absence of visible haematuria, and this is often associated Go to the Trends website ( to see Rik Bryan discussing the diagnosis and management of bladder cancer. with a delay in the diagnosis of UBC. 4 Further investigation of patients suspected of having UBC requires multiple diagnostic procedures, including imaging of the upper urinary tract, urine cytology and cystoscopy, 5,7,8 and in most cases the diagnosis is subsequently confirmed following transurethral resection of a bladder tumour (TURBT). 5,7 At presentation, per cent of patients will be diagnosed with non-muscle-invasive tumours (NMIBC: stages Ta, T1 and Tcis), with the remainder diagnosed with muscle-invasive bladder cancer (MIBC, stages T2 4), and with a male:female preponderance of at least 3:1. 9 Richard T. Bryan, MB ChB, PhD, MRCS, Senior Research Fellow, School of Cancer Sciences, University of Birmingham; on behalf of Action on Bladder Cancer
2 8 (ultrasound, intravenous urography, CT, etc.), although urine cytology and flexible cystoscopy are currently considered essential components. More recently, CT urography (CTU) has demonstrated improved detection rates for upper tract urothelial cancers, renal cancers and stones, and may allow for the more streamlined management of these patients as well as those diagnosed with UBC (Figure 1). 14 There is thus a school of thought suggesting that CTU should become the standard imaging investigation for haematuria (although costs and capacity may be issues for some units), even permitting certain patients to be listed for TURBT without the need for prior flexible cystoscopy. 14 Figure 1. Excretory-phase CT urography image showing layering phenomena and clearly depicting a bladder cancer attached to the left lateral bladder wall Aside from providing grading and local staging, TURBT represents the principal treatment for NMIBC. 7 Further treatment may be required in the form of intravesical therapy, most often with mitomycin C (MMC) or Bacillus Calmette-Guerin (BCG). 5,7 NMIBC is typified by a high rate of recurrence (15 61 per cent at one year, depending upon risk category 10 ) and so long-term, even lifelong, surveillance with outpatient flexible cystoscopy is the mainstay of subsequent management. 5,7 Progression to MIBC is also a concern for high-risk NMIBC patients, occurring in up to 17 per cent of patients at one year, 10 and a small but significant lifetime risk of developing urothelial cancer in the upper urinary tract means that imaging of the upper tracts should be performed every months, depending upon risk category and tumour behaviour. 5 For curative intent, patients who present with or progress to MIBC are treated by radiotherapy, 5,11 chemoradiotherapy, 12 radical cystectomy, or neoadjuvant chemotherapy followed by radical cystectomy. 5,11,13 Systematic reviews of the management of NMIBC and MIBC are regularly undertaken by the European Association of Urology (EAU), whose guidelines direct the management of UBC in Europe and the UK. 7,11 The 2013 updates to the EAU guidelines are available online at DIAGNOSIS OF BLADDER CANCER Haematuria clinic Haematuria clinics represent a oneor two-stop infrastructure for the investigation of patients referred with visible or non-visible haematuria. 6 Patients undergo history and examination, imaging of the upper urinary tract, urinalysis (including urine cytology) and flexible cystoscopy. 5 In the UK, there is no standardised protocol for this series of haematuria clinic investigations and multiple permutations are practised Around 19 per cent of patients presenting with visible haematuria will be diagnosed with a urinary tract malignancy, compared with around 5 per cent presenting with non-visible haematuria. 15 Importantly, a diagnosis of UBC should also be considered in those patients with irritative or UTI-like symptoms in the absence of a UTI, especially in female patients, 4 or in those whose symptoms have not responded to a course of antibiotics. Urinary biomarkers Since per cent of patients present with NMIBC, where recurrence and progression are significant issues, 3,9,16,17 current guidelines recommend long-term surveillance with regular outpatient flexible cystoscopy. 7 Consequently, bladder cancer is one of the most expensive malignancies to manage on a per-patient basis from diagnosis to death, 18 and this has led to over a decade of diagnostic urinary biomarker research in an attempt to overcome the cost and invasive nature of NMIBC surveillance. Several biomarkers are commercially available and are FDA-approved, but no single marker has sufficient sensitivity and specificity to replace cystoscopy. 5,19 However, the latest generation of TRENDS IN UROLOGY & MEN S HEALTH SEPTEMBER/OCTOBER 2013
3 9 experimental platforms shows significant promise in the field of urinary biomarker discovery, identifying protein-, DNA- and RNA-based biomarkers with potential clinical utility. 20,21 A number of studies are ongoing, although for the foreseeable future it is likely that these biomarkers will only reduce the frequency of cystoscopic surveillance and not replace cystoscopy altogether, especially for high-risk NMIBC. However, we are hopeful that the future will see the development of a multi-biomarker urinary test with utility for both the diagnosis and surveillance of UBC. GRADING AND STAGING Grading The 1973 WHO system classifies tumours according to three grades of increasingly aggressive behaviour, grades 1, 2 and 3, whereas the 2004 system classifies tumours as papillary urothelial neoplasm of low malignant potential, low-grade urothelial carcinoma and high-grade urothelial carcinoma. 22 Controversy exists as to the more accurate system for prognostication, although more recent evidence supports use of the 1973 system (G1, G2, G3) for better prediction of recurrence and progression. 22 In the UK, specialist uro-oncology histopathologists use both systems for UBC reporting. Staging The Union for International Cancer Control TNM system is used for the reporting of UBC stage. Ta (UBC confined to the urothelium only), T1 (invasion into the lamina propria) and Tis (carcinoma in situ abnormal flat urothelium, but highly aggressive) are now termed NMIBC by urologists (the term superficial bladder cancer is considered inaccurate and inappropriate 16 ), and stages T2 and above (invasion into the detrusor muscle and beyond) are termed MIBC; the prefix p is utilised when stage category has been confirmed pathologically (eg pta). Subcategories of T1, T2, T3 and T4 (eg T2a, T2b, etc.) are also described, but are beyond Figure 2. Delicate papillary bladder tumour is clearly visible with narrow-band imaging the scope of this review. The N and M categories describe lymph node and distant metastases, respectively. TREATMENT OF NMIBC Transurethral resection of a bladder tumour As well as confirming the diagnosis, and providing pathological specimens for tumour grading and staging, TURBT is considered the principal management of NMIBC. 7 Over the past years there has been significant interest in the use of cystoscopic image enhancement technologies that can improve the thoroughness of resection at TURBT, or that can improve the detection of carcinoma in situ and recurrent tumours. 23 Photodynamic diagnosis (PDD, also known as blue light cystoscopy, and utilising the intravesical photosensitising agent hexaminolevulinate or Hexvix) and narrowband imaging (NBI, an Olympus technology that narrows the bandwidth of light to 415nm and 540nm) have come to the fore, 24 and are being used almost routinely in some units (Figure 2). However, trial and meta-analysis data in support of PDD are conflicting, and the NBI data are less mature; for both technologies, absolute quantitation of the benefits to demonstrate cost-effectiveness remains elusive, although ongoing trials and those trials in set-up may generate these data. This is particularly pertinent for PDD, where the cost of Hexvix is 375 per instillation. Adjuvant therapy The use of adjuvant intravesical chemotherapy (most commonly MMC in the UK) and immunotherapy (BCG) to prevent recurrence are long established in urological practice. 5,7 Where there are no contraindications, a single dose of intravesical MMC should be administered immediately after TURBT. 5,7 Subsequent courses of intravesical therapy are determined by the patient s risk category (based on clinical and pathological factors 7 ), with courses of MMC or BCG recommended for intermediate-risk patients and BCG recommended for highrisk patients. 7 Given the not insignificant side-effects related to intravesical BCG therapy (as well as cost), debate continues as to whether patients should receive one or three years of maintenance treatment following induction. 25 Waiting in the wings as potential alternatives to conventional (passive diffusion) MMC and BCG are device-assisted intravesical therapies utilising electromotive drug administration (EMDA) and heated/hyperthermic agents (chemohyperthermia, CHT). Prospective randomised controlled trial data are awaited for both EMDA and CHT, but they are likely to become important options for adjuvant therapy for NMIBC in the future. Outcomes The European Organisation for Research and Treatment of Cancer (EORTC) risk tables were published in and give absolute values for recurrence and progression rates at one, three and five years based upon a risk score, which is calculated from a number of clinical and pathological factors; they are also available online as the EORTC Bladder cancer calculator. Although very useful as an indicator of the behaviour of low-, intermediate- and high-risk NMIBC, they have not been thoroughly validated in large independent cohorts and the absolute values for recurrence and progression that are generated may not be accurate in light of modern urological practice. However, to date, there is no
4 10 better risk categorisation tool, although large-scale genomic and epigenomic analyses of UBCs in the near future may lead to improved prognostication. For 2013, NMIBC risk categorisation has actually been simplified in the EAU guidelines. TREATMENT OF MIBC Until recently, neoadjuvant chemotherapy followed by radical cystectomy has been considered the gold standard in the UK, EU and USA for the treatment of organconfined MIBC, with up to 50 per cent five-year survival reported. 5,11,13 However, historically the UK has always treated a significant proportion of MIBC patients (up to 50 per cent) with external beam radiotherapy for curative intent. Recent data suggest that chemotherapy radiotherapy regimens can achieve long-term outcomes that rival those achieved with neoadjuvant chemotherapy and radical cystectomy. 12 Chemoradiotherapy is thus a viable alternative to neoadjuvant chemotherapy radical cystectomy, and this is particularly relevant for the rapidly growing proportion of over 80-year-old patients diagnosed with MIBC, 9 for whom the 90-day mortality rates for radical cystectomy are significantly greater than those for younger patients. 26 In reality, data demonstrate that the majority of over 80-year-old patients diagnosed with MIBC in the UK are treated with radiotherapy, although experts consider that cystectomy in this group is safe when carried out in selected patients in specialist high-volume units, and utilising enhanced recovery programmes. The precise details of the chemoradiotherapy regimens and the techniques of radical cystectomy are beyond the scope of this review, but can be found in recent publications and the EAU guidelines. 11,12 However, the choice of surgical approach for radical cystectomy is now between a conventional open approach, laparoscopic, or robot-assisted laparoscopic, depending upon the expertise of individual units and surgeons. The extent of the cystectomy will be determined by disease involvement of the prostate and urethra and the type of reconstruction proposed (urinary diversion/ ileal conduit or neobladdder/orthotopic bladder substitution). 11 Radical cystectomy also involves removal of the regional lymph nodes, and an extended lymph node dissection is now recommended by the 2013 EAU guidelines. Although neoadjuvant chemotherapy has a clear evidence base to support its use 11,13 (UK regimens most commonly utilise gemcitabine and cisplatin), the case for the routine use of adjuvant chemotherapy administered after cystectomy is weak. However, adjuvant chemotherapy may be an individualised recommendation for locally advanced disease or for those with positive lymph nodes, although further trial data are needed; the 2013 EAU guidelines advise that adjuvant chemotherapy should be given only within the setting of a clinical trial. METASTATIC DISEASE When patients present with metastatic disease, treatment focuses around systemic chemotherapy. Gemcitabine cisplatin are most commonly used initially, with MVAC also utilised in this setting (methotrexate, vinblastine, adriamycin or doxorubicin, and cisplatin). 11 Subsequent regimens may utilise MVAC, gemcitabine cisplatin, gemcitabine carboplatin, paclitaxel carboplatin or vinflunine. For metastatic bone disease, the 2013 EAU guidelines recommend zoledronic acid or denosumab, and external beam radiotherapy may be utilised to treat isolated symptomatic bone lesions. DISCUSSION The basis of the diagnosis and management of UBC has remained unchanged for two decades or more, and as a result outcomes have not improved significantly during this period. In addition, there has been a lack of research funding into the disease, especially when compared with other malignancies, even malignancies with a lower incidence and prevalence. We hope that the subtle but important changes in various components of patient management that we have outlined here may translate into improved long-term outcomes for UBC patients, as well as improved health-related quality of life. However, it is imperative that research funding improves, and that innovation and refinement of treatments continue. Acknowledgements I thank Mr Colin Bunce for his critical feedback on the manuscript. Declaration of interests: none declared. REFERENCES 1. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63: Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27: van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56: Wallace DM, Bryan RT, Dunn JA, et al. Delay and survival in bladder cancer. BJU Int 2002;89: Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374: Lynch TH, Waymont B, Dunn JA, et al. Rapid diagnostic service for patients with haematuria. Br J Urol 1994;73: Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59: Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010;116: Bryan RT, Zeegers MP, van Roekel EH, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU Int 2013;112: Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with TRENDS IN UROLOGY & MEN S HEALTH SEPTEMBER/OCTOBER 2013
5 11 stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: Stenzl A, Cowan NC, De SM, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59: James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366: Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48: Cowan NC. CT urography for hematuria. Nat Rev Urol 2012;9: Griffiths TR; Action on Bladder Cancer. Current perspectives in bladder cancer management. Int J Clin Pract 2013;67: Bryan RT, Wallace DM. Superficial bladder cancer time to uncouple pt1 tumours from pta tumours. BJU Int 2002;90: Montgomery JS, Weizer AZ, Montie JE. T1 bladder cancer: advocating early cystectomy to improve oncologic control. Urol Oncol 2010;28: Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol 2008;18: Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60: Zuiverloon TC, Beukers W, van der Keur KA, et al. Combinations of urinary biomarkers for surveillance of patients with incident non-muscle invasive bladder cancer: the European FP7 UROMOL project. J Urol 2013;189: Shimwell NJ, Bryan RT, Wei W, et al. Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. Br J Cancer 2013;108: Chen Z, Ding W, Xu K, et al. The 1973 WHO classification is more suitable than the 2004 WHO classification for predicting prognosis in non-muscleinvasive bladder cancer. PLoS One 2012;7:e Cauberg EC, de Bruin DM, Faber DJ, et al. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur Urol 2009;56: Patel P, Bryan RT, Wallace DM. Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance. Scientific World Journal 2011;11: Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and highrisk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63: Fairey AS, Kassouf W, Aprikian AG, et al. Age >/= 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database. Urol Oncol 2012;30:
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationGuidelines for the Management of Bladder Cancer
Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationInformation for Patients. Bladder Cancer. English
Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationIntravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer Patrick A. Cockerill, John J. Knoedler, Igor Frank, Robert Tarrell and Robert
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationOriginal Article APMC-276
Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationComparative Outcomes of Primary, Recurrent, and Progressive High-risk Non muscle-invasive Bladder Cancer
EUROPEAN UROLOGY 63 (2013) 145 154 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Urothelial Cancer Editorial by J. Alfred Witjes on pp. 155 157 of this
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationBladder Cancer in Primary Care. Dr Penny Kehagioglou Consultant Clinical Oncologist
Bladder Cancer in Primary Care Dr Penny Kehagioglou Consultant Clinical Oncologist Objectives Patient presentation in primary care Investigating bladder cancer Management of bladder cancer Differential
More information14th Meeting of the EAU Section of Oncological Urology (ESOU)
Is Bacillus Calmette-Guerin (BCG) still the best adjuvant treatment after Trans Urethral Resection (TUR) for Ta-T1 high grade (G3) bladder cancer M. Brausi, Modena (IT) Introduction Bacillus Calmette-Guerin
More informationCYSVIEW. CONFIDENCE AT FIRST SIGHT
CYSVIEW. CONFIDENCE AT FIRST SIGHT Blue Light Cystoscopy with CYSVIEW Cysview Indication Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary
More informationEuropean Association of Urology. Pocket Guidelines edition
European Association of Urology Pocket Guidelines 2012 edition Introduction The EAU Guidelines Office is pleased to present the 2012 edition of the Pocket Guidelines. These ultra-short versions of Europe
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of electrically-stimulated intravesical chemotherapy for superficial bladder
More informationEAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines
More informationOrgan-sparing treatment of invasive transitional cell bladder carcinoma
Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,
More informationFrequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience
2nd Annual Surgical Meeting 2016 S-125 UROLOGY ORIGINAL ARTICLE Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience Muhammad Farhan, Syed
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationClinical Policy Title: Enhanced cystoscopy for bladder cancer
Clinical Policy Title: Enhanced cystoscopy for bladder cancer Clinical Policy Number: 13.01.04 Effective Date: April 1, 2017 Initial Review Date: February 15, 2017 Most Recent Review Date: March 15, 2017
More informationClinical Policy Title: Enhanced cystoscopy for bladder cancer
Clinical Policy Title: Enhanced cystoscopy for bladder cancer Clinical Policy Number: 13.01.04 Effective Date: April 1 2017 Initial Review Date: February 15 2017 Most Recent Review Date: March 6, 2018
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationHow do I prepare for treatment? What happens afterwards? Where can I get more information? Cancerbackup The Prostate Cancer Charity
How do I prepare for treatment? Do not drink fluids for at least two hours before treatment so that your bladder will be empty. Tell your doctor or nurse about any medicines you take regularly and any
More informationUpdate on Haematuria and Bladder Cancer
Update on Haematuria and Bladder Cancer Hugh Mostafid FRCS(urol) FEBU Consultant Urologist, Royal Surrey County Hospital and Honorary Senior Lecturer, University of Surrey Guildford None Declarations Recent
More informationUPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014
UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014 *Johannes Bründl, Philipp J. Spachmann, Maximilian Burger Department of Urology, University of Regensburg, Caritas
More information3.1 Investigations for Patients Presenting with Haematuria Table 1
3.1 Investigations for Patients Presenting with Haematuria Table 1 Patients at risk of bacterial endocarditis should be given antibiotic prophylaxis as per local guidelines. Patients with heart valve replacements
More informationThe innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).
pat hways ADXBLADDER for detecting bladder cancer Medtech innovation briefing Published: 12 April 2019 nice.org.uk/guidance/mib180 Summary The technology described in this briefing is ADXBLADDER. It is
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationBladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
More informationTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas
More informationMixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationCase 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:
Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two
More informationOptimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS
Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.
More informationCitation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.
UvA-DARE (Digital Academic Repository) Advancements in diagnostic imaging for urothelial carcinoma Cauberg, E.C.C. Link to publication Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements
More informationRole of Re-Resection in Non Muscle-Invasive Bladder Cancer
Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.
More informationUrothelial carcinomas of the upper urinary tract how does UK practice compare with European guidelines: is there a difference?
699543URO0010.1177/2051415817699543Journal of Clinical UrologyMoon et al. research-article2018 EAU Guidelines Urothelial carcinomas of the upper urinary tract how does UK practice compare with European
More informationCitation International journal of urology (2. Right which has been published in final f
Title Novel constant-pressure irrigation of renal pelvic tumors after ipsila Nakamura, Kenji; Terada, Naoki; Sug Author(s) Toshinori; Matsui, Yoshiyuki; Imamu Kazutoshi; Kamba, Tomomi; Yoshimura Citation
More informationTHE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER
THE USE OF HALF DOSE BCG FOR INTRAVESICAL IMMUNOTHERAPY IN NON MUSCLE INVASIVE BLADDER CANCER Mihály Zoltán Attila 1, Rusu Cristian Bogdan 2, Mihály Orsolya Maria 3, Bolboacă Sorana Daniela 4, Bungărdean
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationCUA guidelines on the management of non-muscle invasive bladder cancer
Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney
More informationSUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationIAUN Conference Dublin, January Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist
IAUN Conference Dublin, January 2014 Helen Forristal Cancer Nurse Co- Ordinator Jonathan Borwell Bladder Cancer Clinical Nurse Specialist Theoretical component Observation Supervised practice Assessment
More informationBCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients
BCG Failure or BCG Unresponsive: Defining and Managing Difficult Patients Michael S. Cookson, MD, Professor and Chair Department of Urology University of Oklahoma Non-muscle Invasive Bladder Cancer Bladder
More information10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?
Case # 1 An underwriter enters your office, hands you a sheet of paper, and asks What do you think? Can we make an offer? You look at the paper and see it s lab results on a 60 year male looking for $500,000
More informationInformation for Patients. Primary urethral cancer. English
Information for Patients Primary urethral cancer English Table of contents What is primary urethral cancer?... 3 Risk factors... 3 Symptoms... 4 Diagnosis... 4 Clinical examination... 4 Urinary cytology...
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial
More informationMANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS
MANAGING PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: OLD DISEASE, NEW IDEAS This symposium took place on 12 th March 2016 as part of the European Association of Urology Congress 2016 in Munich, Germany
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationThe value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice
48 Original Paper UROLOGICAL ONCOLOGY The value of EORTC risk tables in evaluating recurrent non muscle invasive bladder cancer in everyday practice Rafał Walczak, Krzysztof Bar 2, Janusz Walczak Department
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationPanel: A Case-based Approach to the Management of Bladder Cancer
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationEAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)
EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) M. Babjuk (Chair), M. Burger (Vice-Chair), E. Compérat, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S.F. Shariat,
More informationManagement options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
More informationClinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer
Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer Reference: NHS England B14X08 Information Reader Box (IRB) to be inserted on inside front cover for documents of 6
More informationIntroduction. Bladder cancer is the second most common genitourinary malignancy in the United States and the fifth most
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride
More informationRITE Thermochemotherapy in the treatment of BCG refractory NMIBC
RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or
More information